Relay Therapeutics plans to initiate ReDiscover-2, a Phase 3 trial evaluating RLY-2608 plus fulvestrant in PI3Kα-mutated, HR+/HER2- advanced breast cancer patients, with enrollment target of 540 patients.
Updated clinical data on RLY-2608 plus fulvestrant will be presented at the San Antonio Breast Cancer Symposium, showcasing its efficacy in advanced breast cancer.
Allosteric PIK3CA inhibitors, like STX-478 and RLY-2608, offer a more targeted approach with improved safety profiles compared to orthosteric inhibitors.
Roche's Itovebi, combined with palbociclib and fulvestrant, shows statistically significant and clinically meaningful overall survival (OS) benefit in advanced breast cancer.
RLY-2608 combined with fulvestrant demonstrates clinically meaningful progression-free survival in heavily pretreated patients with PI3Kα-mutated, HR+/HER2- breast cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.